These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Identification of fluorinated (R)-(-)-aporphine derivatives as potent and selective ligands at serotonin 5-HT Xu Y; Sromek AW; Neumeyer JL Bioorg Med Chem Lett; 2019 Jan; 29(2):230-233. PubMed ID: 30545651 [TBL] [Abstract][Full Text] [Related]
45. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. Rauser L; Savage JE; Meltzer HY; Roth BL J Pharmacol Exp Ther; 2001 Oct; 299(1):83-9. PubMed ID: 11561066 [TBL] [Abstract][Full Text] [Related]
46. Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model. Zhang X; Andren PE; Svenningsson P Physiol Behav; 2007 Sep; 92(1-2):29-33. PubMed ID: 17588622 [TBL] [Abstract][Full Text] [Related]
47. New horizons for selective 5-HT2C receptor ligands in psychiatric/neurological disorders. Rosenzweig-Lipson S Neuropsychopharmacology; 2011 Jan; 36(1):363-4. PubMed ID: 21116257 [No Abstract] [Full Text] [Related]
48. The roles of histamine and its receptor ligands in central nervous system disorders: An update. Hu W; Chen Z Pharmacol Ther; 2017 Jul; 175():116-132. PubMed ID: 28223162 [TBL] [Abstract][Full Text] [Related]
51. Serotonin in Health and Disease. De Deurwaerdère P; Di Giovanni G Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429111 [TBL] [Abstract][Full Text] [Related]
52. Prime time for G-protein-coupled receptor heteromers as therapeutic targets for CNS disorders: the dopamine D₁-D₃ receptor heteromer. Ferré S; Lluis C; Lanciego JL; Franco R CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):596-600. PubMed ID: 20632968 [TBL] [Abstract][Full Text] [Related]
53. Structure-Activity Relationships and Therapeutic Potentials of 5-HT Modica MN; Lacivita E; Intagliata S; Salerno L; Romeo G; Pittalà V; Leopoldo M J Med Chem; 2018 Oct; 61(19):8475-8503. PubMed ID: 29767995 [TBL] [Abstract][Full Text] [Related]
54. Preclinical and clinical studies with somatostatin related to the central nervous system. Vécsei L; Widerlöv E Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(4):473-502. PubMed ID: 1978375 [TBL] [Abstract][Full Text] [Related]
55. Soto CA; Du HC; Fox RG; Yang T; Hooson J; Anastasio NC; Gilbertson SR; Cunningham KA Front Pharmacol; 2019; 10():907. PubMed ID: 31507411 [TBL] [Abstract][Full Text] [Related]
56. Neuropharmacological potentials of β-carboline alkaloids for neuropsychiatric disorders. Ayipo YO; Mordi MN; Mustapha M; Damodaran T Eur J Pharmacol; 2021 Feb; 893():173837. PubMed ID: 33359647 [TBL] [Abstract][Full Text] [Related]
57. Polypharmacology of dopamine receptor ligands. Butini S; Nikolic K; Kassel S; Brückmann H; Filipic S; Agbaba D; Gemma S; Brogi S; Brindisi M; Campiani G; Stark H Prog Neurobiol; 2016 Jul; 142():68-103. PubMed ID: 27234980 [TBL] [Abstract][Full Text] [Related]
58. Neuropeptides: general characteristics and neuropharmaceutical potential in treating CNS disorders. Strand FL Prog Drug Res; 2003; 61():1-37. PubMed ID: 14674607 [TBL] [Abstract][Full Text] [Related]
59. Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases. Di Giovanni G; Svob Strac D; Sole M; Unzeta M; Tipton KF; Mück-Šeler D; Bolea I; Della Corte L; Nikolac Perkovic M; Pivac N; Smolders IJ; Stasiak A; Fogel WA; De Deurwaerdère P Front Neurosci; 2016; 10():541. PubMed ID: 27932945 [TBL] [Abstract][Full Text] [Related]
60. Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases. Tarazi FI J Sci Res Med Sci; 2001 Oct; 3(2):93-104. PubMed ID: 24019715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]